Trastuzumab deruxtecan
Enhertu (trastuzumab deruxtecan) is an antibody pharmaceutical. Trastuzumab deruxtecan was first approved as Enhertu on 2019-12-20. It is used to treat breast neoplasms and gastrointestinal neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. It is known to target receptor tyrosine-protein kinase erbB-2.
| Trade Name | Enhertu |
|---|---|
| Common Name | Trastuzumab deruxtecan |
| Indication | breast neoplasms, gastrointestinal neoplasms |
| Drug Class | Monoclonal antibodies: humanized, tumors as target; antineoplastics (camptothecine derivatives) |
